WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 11, 397-405. Review Article ISSN 2277–7105

BIOSIMILAR PRODUCTS: FUTURE LOW COST OPHTHALMIC PREPARATION ANDLOW COST MEDICINE IN THE GLOBAL MARKET

Megha Jha*[1], Aditi Kushare[2], Prem Jadhav[3] and Mansi Jadhav[4]

[1]Student MGV's Pharmacy College (Affiliated to Savitribai Phule Pune University), Panchavati,Nashik-422003, Maharashtra, India.
[2]Assistant Professor, Department of Pharmaceutical Quality Assurance MGV's Pharmacy College (Affiliated to Savitribai Phule Pune University), Panchavati, Nashik-422003, Maharashtra, India.
[3]Student MGV's Pharmacy College (Affiliated to Savitribai Phule Pune University), Panchavati, Nashik-422003, Maharashtra, India.
[4]Student MGV's Pharmacy College (Affiliated to Savitribai Phule Pune University), Panchavati, Nashik-422003, Maharashtra, India.

Article Received on
09 April 2024,

Revised on 29 April 2024,
Accepted on 19 May 2024

DOI: 10.20959/wjpr202411-32548

***Corresponding Author**
Megha Jha
Student MGV's Pharmacy College (Affiliated to Savitribai Phule Pune University), Panchavati, Nashik-422003, Maharashtra, India.

ABSTRACT

A biosimilar birth medical product is a nearly exact replica of an original product produced by a separate business. A well-equipped exploration and development facility is the only place where biosimilars may be produced when the patent on the original product expires. Biosimilars are officially recognised imitations of original "inventor" items. For no supervision to be granted, a biosimilar must show no clinically significant variations in quality, safety, and effectiveness from its originator equivalent. It shouldn't be mistaken with a generic drug, whose chemical structure is easy to duplicate; once again, biosimilars aren't exact replicas of the originals since they differ from the latter in ways that aren't clinically significant. The fact that biosimilars are ultimately more susceptible to heterogeneity owing to minute modifications in their manufacturing process is another significant distinction between generic medications and biosimilars. The blood-aqueous barrier and the blood-retinal barrier (BRB) make up the blood-ocular barrier system. A physiological barrier that controls ion, protein, and water flow into and out of the retina, the BRB is very tight and constrictive. Both the inner and outer parts of the BRB are made up of tight connections between retinal capillary endothelial cells, whereas the outer part is made up of tight junctions between retinal pigment

epithelial cells. Both keeping the eye as a privileged location and ensuring appropriate visual function depend on the BRB. Changes to the BRB are very important in the development of retinal disorders.

KEYWORDS: Biosimilar, Blood–retinal barrier, blood–ocular barriers, ophthalmology.

INTRODUCTION

1. What exactly is a biosimilar product?

A biosimilar is a natural product that resembles an FDA-approved reference product in most ways and differs from it in no way that would have therapeutic significance. More details on these two morals are provided below.

2. What does "largely similar" imply exactly?

In clinically inactive characteristics, there are reasonable discrepancies between the proposed biosimilar product and the reference product. By thoroughly assessing (i.e., characterising) the structure and function of both the reference product and the proposed biosimilar, the maker of the proposed biosimilar proves that their product is substantially comparable to the reference product. Modern technology is employed to compare product attributes such as chastity, chemical identity, and bioactivity. The producer demonstrates that the biosimilar is substantially comparable to the reference product using the outcomes of these comparative tests, in addition to additional data. In clinically inactive characteristics, there are respectable variations between the reference product and the proposed biosimilar product. For instance, they might be slight variations in the stabiliser or buffer used in the test product compared to the reference product. To make sure the proposed biosimilar product complies with FDA's strict approval standards, any changes between it and the reference product are carefully estimated by FDA. As previously stated, minor variances (i.e., reasonable within-product fluctuations) are expected during the manufacturing process for natural goods, regardless of whether the product is a biosimilar or a reference product. Lot-to-lot variances, or reasonable within product discrepancies, are carefully managed and covered for both reference products and biosimilars.

3. What does "no clinically meaningful differences" imply exactly?

A producer must also show that the safety, chastity, and energy (safety and efficacy) of its proposed biosimilar product are not clinically different from those of the reference medicine. This is often shown by research on lethal pharmacokinetic exposure, pharmacodynamics

response, clinical immunogenicity evaluation, and, if necessary, further clinical investigations.

4. Are biosimilars equivalent to generic medications?

Generic and biosimilar medications are copies of name-brand medications and may provide patients with more economical treatment choices. Generic drugs and biosimilars are both licenced using streamlined processes that avoid repeating expensive clinical trials. However, biosimilars are not the same as generic medications, and they differ from them in several significant ways. For instance, brand-name and generic medications both contain the same active components. Furthermore, the generic drug's maker must show that it is bioequivalent to the brand-name medication. Contrarily, producers of biosimilars must show that their products are very comparable to the original, with the exception of slight variations in components that have no effect on patients. Additionally, biosimilar producers must show that there are no clinically significant changes in the safety and efficacy of the biosimilar compared to the reference product.[1,2]

BIOSIMILAR PROSPECTS FOR OPHTHALMOLOGY

Since the discovery of anti-vascular endothelium-derived growth factors (anti-VEGF) more than 15 years ago, ophthalmology, and particularly retina as a specialisation, have undergone significant change. Ranibizumab (Lucentis®; Genentech, Inc., South San Francisco, CA, USA), aflibercept (Eylea®; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA), and off label bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA, USA) are examples of innovative anti-VEGF molecules that have been approved.[3,4] A new age of biosimilars has emerged as a result of patent expirations.[3] The patent on ranibizumab expires in 2020, and the patent on aflibercept will shortly expire (2023).[4] Intas Pharmaceuticals Ltd.'s ranibizumab, produced in Ahmedabad, Gujarat, India, was the first ranibizumab biosimilar to receive approval outside of the United States in 2015.[4]

Only India was given permission to utilise this biosimilar. On August 18, 2021, the US Food and Drug Administration (FDA) and the European Medicines Agency authorised ranibizumab nuna (ByoovizTM, Biogen, Cambridge, MA, USA) as a biosimilar to ranibizumab.[7] There are at least 20 ranibizumab, aflibercept, and bevacizumab biosimilar compounds under development.[8] Biosimilars are new to the field of ophthalmology, but other subspecialties, including rheumatology, dermatology, gastrointestinal, cancer, and haematology, have effectively employed them.[5] The potential of biosimilars and bio betters

in ophthalmology is highlighted in this paper. It is difficult to anticipate the future of biosimilars in ophthalmology at this time since the specialty differs from others due to a number of characteristics that set industrialised countries apart from underdeveloped nations.[9] The availability of inexpensive, off-label compounded bevacizumab is a key differentiator.

Biosimilars have a better future in developing nations like India than in wealthy nations where bevacizumab compounding is safe since these nations lack a strong system of pharmacies that can produce bevacizumab. Bevacizumab-vikg (ONS-5010/LytenavaTM; Outlook Therapeutics, Inc., Iselin, NJ, USA), an on-label bevacizumab that is considered an innovative medication rather than a biosimilar but has the potential to alter the market dynamics, has been developed in response to this circumstance.(6) Ranibizumab biosimilar use has been steadily rising since its introduction in India, according to a recent report by the Vitreo Retina Society of India.[7] Recently, many more ranibizumab biosimilars, including RanizuRelTM (Reliance Life Science, Mumbai, India), have been introduced in India.[8] Lupin Limited (Mumbai, India) will shortly release a second ranibizumab biosimilar.[4] The fact that biosimilars are consistently produced suggests that ophthalmology-related businesses recognise the growing potential of such goods.[9]

Blood–Retinal Barrier

The BRB, which is made up of inner and outer components (iBRB and oBRB), is crucial to the microenvironment of the retina and retinal neurons. It controls the flow of fluids and chemicals between the retinal tissues and the ocular vascular beds, preventing the leaking of macromolecules and other potentially damaging substances into the retina (see Figures 1 and 2).



Figure 1: The Blood's Main Fluid Movements and Ocular Barriers are schematically illustrated.

The tight connections (zonulae occludentes) between nearby retinal endothelial cells form the iBRB.[10,11] The retinal endothelial layer performs the role of a "epithelium," and as a result, its development and the polarisation of BRB function are intimately related. The major structural component of the iBRB, a continuous endothelial cell layer, lies atop a basal lamina that is coated in astrocyte and Müller cell processes. Although pericytes are also present and are in close proximity to the endothelial cells in the basal lamina, they do not form a continuous layer and do not consequently contribute to the diffusional barrier. Through the transmission of regulatory signals to endothelial cells that indicate changes in the milieu of the retinal neural circuitry, astrocytes, Müller cells, and pericytes are thought to have an impact on the activity of retinal endothelial cells and the iBRB. The tight connections (zonulae occludentes) connecting nearby retinal pigment epithelial (RPE) cells form the oBRB.[12,13] The retinal pigment epithelial cells that make up the RPE are arranged in a single layer and are connected laterally towards their apices by tight connections between neighbouring lateral cell walls. The RPE, which is supported by the underlying Bruch's membrane, divides the neural retina from the fenestrated choriocapillaries and controls how nutrients from the blood reach the photoreceptors as well as how waste is removed and retinal adhesion is maintained. The metabolic interaction between the RPE apical villi and photoreceptors is thought to be crucial for maintaining visual function. Tight cell connections prevent fluid and molecular paracellular transport between the blood and retina in the iBRB and the oBRB, and endothelial cells and.



Figure 2: The Inner and Outer Blood-Retinal Barriers, together with their respective locations, are representedschematically.

RPE cells actively control inward and outward moment.[14] As a result, the quantities of amino acids and fatty acids in the plasma fluctuate widely, but their concentrations in the retina stay relatively steady. Müller cells and blood vessels in the retina have a close spatial relationship, indicating that these cells play a crucial role in the development and maintenance of the BRB and in controlling barrier cells' normal functions of nutrient uptake and metabolite disposal.

Matrix metalloproteinase (MMPs) produced by Müller cells, which cause the tight-junction proteinoccludin to be degraded by proteolysis, also decrease barrier function.

IMPORTANT MARKET INSIGHTS

The market for ophthalmology biosimilars is anticipated to expand rapidly during the next years. The prevalence of ophthalmic disorders, the return of retinal diseases, the increase in the elderly population, the rise in diabetes cases, and other reasons are the main ones that are positively affecting the market's growth. The global prevalence of age-related macular degeneration is expected to be 8.7% for early age-related macular degeneration and 0.4% for late age-related macular degeneration in people between the ages of 45 and 85. Additionally, enhanced medication delivery for better healthcare outcomes, rising use of biosimilars by healthcare professionals for better patient treatment, and others are significantly fueling the market's growth throughout the projection period. Furthermore, an increase in research and development activities to improve the drug pipeline based on market trends, as well as various initiatives conducted by the government and other healthcare organisations to raise awareness about ophthalmic diseases and the use of biosimilars in treatment, are expected to

significantly propagate market growth in the coming years.

However, due to advances in drug delivery in the pharmaceutical and biotechnological areas, rising medication costs and treatment are likely to stifle expansion due to worries about patient access to continue medicines. Blockbuster biologics' patents have also expired, which has had a detrimental impact on their manufacture and slowed the market's potential development.

Segmentation of The Market

The ophthalmology biosimilars market is categorised globally based on medication type, indication, distribution method, and geographic location. The market is divided into categories for Adalimumab, Aflibercept, Ranibizumab, and other drugs based on the kind of medicine. The market is divided into segments for macular degeneration, diabetic macular edoema, retinal detachment, and others depending on the indication. The market is divided into hospital pharmacies, retail pharmacies & drug shops, internet pharmacies, and others based on the distribution route. The ophthalmology biosimilars market is divided into five geographic segments: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The Key Players Covered

The leading organisations profiled in the study on the worldwide ophthalmology biosimilars market are Zydus Cadila, Biocon, Formycon AG, Xbrane Biopharma, Pfenex Inc., Coherus BioSciences, Biocad, Allergen, mAbxience, Intas Pharmaceuticals Ltd., and others.

The Key Insights

- Ophthalmic disease prevalence in important countries.
- Compensation Scenario for Important Countries.
- Important Acquisitions and Mergers.
- Product Introductions.
- Pipeline Evaluation for Biosimilars in Ophthalmology.

CONCLUSION

- Increase access to life-saving medications: Biosimilars are often less expensive than their reference biologic drugs, making them more accessible for patients and healthcare systems. Biosimilar products are safe and effective treatment choices. This may result in

more peoplehaving access to these necessary treatments.

- Increased treatment options: Patients now have additional alternatives for biologic drugs thanks to the availability of biosimilars. Patients who don't respond well to one biologic or who encounter negative effects may find this to be useful.
- Lower healthcare expenses: Patients and healthcare systems can both benefit from lower healthcare costs thanks to biosimilars. This is because they are often less costly than the biologic items that serve as their references.
- Biosimilars are a useful improvement to the healthcare system. They assist in easing the financial strain on healthcare systems while providing patients with safe and affordable treatment alternatives.

ABBREVIATIONS

BRB: Blood–Retinal Barriers; iBRB: inner Blood–Retinal Barriers;

oBRB: outer Blood–Retinal Barriers;

MMPs: Matrix metalloproteinase;RPE: retinal pigment epithelial;

REFERENCES

1. Sharma A, Kumar N, Parachuri N, et al. Biosimilars for retinal diseases: An update. Am J Ophthalmol, 2021; 224: 36–42.
2. Sharma A, Kumar N, Kuppermann BD, et al. Biologics, biosilimars, and biobetters: Different terms or different drugs? Eye (Lond), 2019; 33: 1032–4.
3. Hemmington A, Dalbeth N, Jarrett P, et al. Medical specialists' attitudes to prescribing biosimilars. Pharmacoepidemiol Drug Saf, 2017; 26: 570–7.
4. Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014; 27: 44–6.
5. Hemmington A, Dalbeth N, Jarrett P, et al. Medical specialists' attitudes to prescribing biosimilars. Pharmacoepidemiol Drug Saf, 2017; 26: 570–7.
6. Sharma A, Kumar N, Parachuri N, et al. On label bevacizumab for retina: Where it stands.Eye (Lond), 2022; 36: 916–7.
7. Sheth JU, Stewart MW, Khatri M, et al. Changing trends in the use of anti-vascular endothelial growth factor (antiVEGF) biosimilars: Insights from the Vitreoretinal Society ofIndia Biosimilars of Anti-VEGF Survey. Indian J Ophthalmol, 2021; 69: 352– 6.
8. Sharma A, Arunaprakash J, Das A, et al. Ranizurel safety evaluation in real-world - (RaSER)study. Am J Ophthalmol Case Rep, 2022; 25: 101358.

9. GlobeNewswire. Ophthalmology Biosimilars Market Report 2028 | Size, share, growth, trends, competitive landscape, revenue, forecast. 2021. Available at: www.globenewswire.com/newsrelease/2021/09/07/2292273/0/en/Ophthalmology BiosimilarsMarket-Report-2028-Size-Share-Growth-Trends-CompetitiveLandscape Revenue-Forecast.html (accessed 19 May 2022).
10. Cunha-Vaz JG, Shakib M, Ashton N, Studies on the permeability of the blood-ocular barrier. I. On the existence, development and site of a blood–retinal barrier, Br J Ophthalmol, 1966; 50: 411–53.
11. Shakib M, Cunha-Vaz JG, Studies on the permeability of the blood-retinal barrier. IV. Junctional complexes of the retinal vessels and their role on their permeability, Exp Eye Res, 1966; 5: 229–34.
12. Peyman GA, Bok D, Peroxidase diffusion in the normal and laser-coagulated primate retina, Invest Ophthalmol, 1972; 11: 35–45.
13. Strauss O, The retinal pigment epithelium in visual function, Physiol Rev, 2005; 85: 845–81.
14. Philips BE, Antonetti DA, Blood–retinal barrier. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ (eds), Retinal Vascular Disease, Berlin: Springer-Verlag, 2007; 139–53.